rozanolixizumab 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
chimeric/humanized	5735	1584645-37-3

Description:

Molecule

Description

Synonyms:

rozanolixizumab
rozanolixizumab-noli
UCB7665
rystiggo

Rozanolixizumab-noli is a humanized IgG4 monoclonal antibody that binds to the neonatal Fc receptor (FcRn), resulting in the reduction of circulating IgG.

Molecular weight:
Formula:
CLOGP:
LIPINSKI: None
HAC: None
HDO: None
TPSA:
ALOGS:
ROTB: None

Drug dosage:

None

ADMET properties:

None

Approvals:

Date	Agency	Company	Orphan
June 26, 2023	FDA	UCB INC

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

None

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
MeSH PA	D007155	Immunologic Factors
MeSH PA	D007166	Immunosuppressive Agents
FDA EPC	N0000194004	Neonatal Fc Receptor Blocker
FDA MoA	N0000194005	Neonatal Fc Receptor Blockers

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Generalized myasthenia gravis	indication	91637004	DOID:437

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
IgG receptor FcRn large subunit p51	Membrane receptor	P55899	FCGRN_HUMAN	ANTIBODY BINDING	Kd	10.47		SCIENTIFIC LITERATURE	DRUG LABEL

External reference:

ID	Source
CHEMBL4297820	ChEMBL_ID
C000627812	MESH_SUPPLEMENTAL_RECORD_UI
9801	IUPHAR_LIGAND_ID
DB14919	DRUGBANK_ID
019481	NDDF
4042357	VANDF
4042358	VANDF
C4726717	UMLSCUI
10213	INN_ID
2642273	RXNORM
D12182	KEGG_DRUG
P7186074QC	UNII
368620	MMSL
41734	MMSL
d10075	MMSL

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
RYSTIGGO	HUMAN PRESCRIPTION DRUG LABEL	1	50474-980	INJECTION, SOLUTION	140 mg	SUBCUTANEOUS	BLA	27 sections